Patent US5093505A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5093505A Expired / Lapsed US ⏱️ 0.0 years remaining

Novel heterocyclic compound, carcinostatic agent, and carcinoma controlling method

Assignee: Wakunaga Pharmaceutical Co Ltd
•
Filing: 1990-05-25
•
Granted: 1992-03-03
•
Expires: 2010-05-25
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Heterocyclic compounds of the general formula: ##STR1## wherein R 11 is a hydroxyl group or a lower alkoxy group, R 12 is a lower alkoxy group, R 13 is a saturated or unsaturated hydrocarbon group, X is an oxygen atom or a sulfur atom, and Y is an oxygen atom or --NH-- which may have a lower alkyl substituent, or salts thereof are novel and effective in controlling carcinoma.

Inventors

  • 👤 Hoyoku Nishino
  • 👤 Yukihiro Kodera
  • 👤 Toshihiko Sumida
  • 👤 Susumu Yoshida
  • 👤 Hiromichi Matsuura
  • 👤 Yoichi Itakura

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 18:59
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/62; C07D213/69; A; A61; A61P; A61P35/00; C07D213/70; C07D309/00; C07D309/34; C07D309/36; C07D309/40

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 53 words
A heterocyclic compound of the general formula: ##STR6## wherein R 11 is a hydroxyl group or a lower alkoxy group, R 12 is a lower alkoxy group, R 13 is a lower alkyl group, X is an oxygen atom or a sulfur atom, and Y is an oxygen atom, or a salt thereof.
Claim 2
Dependent Claim 53 words
A heterocyclic compound of the general formula: ##STR6## wherein R 11 is a hydroxyl group or a lower alkoxy group, R 12 is a lower alkoxy group, R 13 is a lower alkyl group, X is an oxygen atom or a sulfur atom, and Y is an oxygen atom, or a salt thereof.
Claim 3
Dependent Claim 41 words
A carcinostatic composition, comprising an effective amount of a heterocyclic compound or a salt thereof as set forth in claim 1 as an active ingredient and a pharmaceutically acceptable carrier, wherein said effective amount is from 10 mg to 10 grams.
Claim 4
Dependent Claim 18 words
The heterocyclic compound of claim 1, which is selected from the group consisting of 3-hydroxy-6-methyl-5-methoxy-2-pentyl-4H-pyran-4-one, 6-methyl-3,5-dimethoxy-2-pentyl-4H-pyran-4-one, and 3-hydroxy-6-methyl-5-methoxy-2-pentyl-4H-pyran-4-thione.
Claim 5
Dependent Claim 21 words
The heterocyclic compound of claim 1, wherein R 13 is a saturated linear alkyl group having 1 to 6 carbon atoms.
Claim 6
Dependent Claim 13 words
The heterocyclic compound of claim 4, wherein R 13 is a methyl group.
Claim 7
Dependent Claim 25 words
The carcinostatic composition of claim 2, wherein said heterocyclic compound is selected from the group consisting of 3-hydroxy-6-methyl-5-methoxy-2-pentyl-4H-pyran-4-one, 6-methyl-3,5-dimethoxy-2-pentyl-4H-pyran-4H-pyran-4-one, and 3-hydroxy-6-methyl-5methoxy-2-pentyl-4H-pyran-4-thione, hydroxy-6-methyl-5-methoxy-2-pentyl-4-pyridone, hydroxy-1,6-dimethyl-5-methoxy-2-pentyl-4-pyridone, and hydroxy-1,6-dimethyl-5-methoxy-2-pentyl-4-pyridinethione.

References Cited (Backward Citations)

US4891361A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1995-03-03 1995-09-02 1996-03-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1999-03-03 1999-09-02 2000-03-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2003-03-03 2003-09-02 2004-03-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag